It is increasingly recognized that the abnormal physiologic consequences of pulmonary
hypertension (PH) may contribute to poor cardiopulmonary health in premature babies …

Approximately 8–42% of premature infants with chronic lung disease of prematurity,
bronchopulmonary dysplasia (BPD), develop pulmonary hypertension (PH). Infants with …

Pediatric pulmonary hypertension (PPH) is a multifactorial disease with diverse etiologies
and presenting features. Pulmonary hypertension (PH), defined as elevated pulmonary …

Objectives To provide an updated review and meta‐analysis on the efficacy and safety of
sildenafil for treating persistent pulmonary hypertension in neonates (PPHN). Methods …

Background PPHN is often a complication of many lung diseases and systemic disorders
that lead to elevated PVR. 1, 2 The fetal pulmonary circulation is characterized by elevated …

Iloprost is a selective pulmonary vasodilator approved for inhalation by the Food and Drug
Administration. Iloprost has been increasingly used in the management of critically ill …

Cyclooxygenase-2 (COX-2/PTGS2) mediates hyperoxia-induced impairment of lung
development in newborn animals and is increased in the lungs of human infants with …

Objective The study aimed to evaluate the effects of inhaled iloprost on oxygenation indices
in neonates with persistent pulmonary hypertension of the newborn (PPHN). Study Design …

经鼻同步间歇指令通气在重度呼吸窘迫综合征早产儿撤机后的应用- PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …

Persistent pulmonary hypertension of the newborn (PPHN) is one of the diseases of the
neonate with severe potential morbidity and mortality. Inhaled iloprost, a stable prostacyclin …